Humulin M3 (30/70) Kwikpen (Insulin Human)

Humulin M3 (30/70) Kwikpen is indicated for the management of hyperglycemia in adults with diabetes.

• Type 1 diabetes mellitus when a basal‑bolus regimen is required.
• Type 2 diabetes mellitus inadequately controlled with oral agents alone.
• Patients who need a convenient premixed insulin to simplify injection schedules.
• Adjunct therapy during periods of increased insulin demand, such as illness or stress.
• Use in combination with lifestyle measures, including diet and exercise, to achieve glycemic targets.

• Humulin M3 contains human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface and increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, reducing endogenous glucose production. The rapid‑acting component acts within minutes, while the protaminated fraction provides a prolonged basal effect.

Adverse reactions to Humulin M3 (30/70) Kwikpen are reported in clinical practice and may vary in frequency and severity.

Common

• Mild hypoglycemia, especially if meals are delayed or carbohydrate intake is insufficient.
• Injection site reactions such as redness, swelling, or itching.
• Weight gain associated with improved glycemic control.
• Transient lipodystrophy at the injection site.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions, including urticaria, angioedema, or anaphylaxis.
• Hypersensitivity with eosinophilia or serum sickness–like symptoms.
• Persistent or painful lipohypertrophy that interferes with insulin absorption.

Before initiating Humulin M3 (30/70) Kwikpen, healthcare providers should evaluate patient-specific factors and monitor for conditions that could affect insulin therapy.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Review history of hypoglycemia unawareness or recurrent severe episodes.
• Consider pregnancy status; insulin requirements may change during gestation.
• Avoid use in patients with known hypersensitivity to human insulin or excipients.
• Educate patients on proper injection technique to reduce lipodystrophy risk.
• Monitor blood glucose regularly and adjust dose based on fasting and post‑prandial values.

Humulin M3 (30/70) Kwikpen can interact with other medicines that influence glucose metabolism or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulins or insulin analogues without dose adjustment.
• Beta‑blockers that may mask hypoglycemia symptoms.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Corticosteroids, which may raise insulin requirements.
• Thiazide diuretics, which can affect glucose tolerance.
• Alcohol consumption, which can cause delayed hypoglycemia.